Quarterly ResultAug 13, 2026, 04:48 PM
VolitionRx Q2 2026 Net Loss $(7.33M) Post Reverse Split
AI Summary
VolitionRx Limited reported a net loss attributable to stockholders of $(7.33) million for Q2 2026, compared to $(6.28) million in Q2 2025. Total revenues for the quarter were $398,657, a slight decrease from $406,688 in the prior year. The company completed a one-for-twenty reverse stock split in April 2026. Despite continued losses, cash and cash equivalents increased significantly due to financing activities, and the net loss per share improved.
Key Highlights
- Net loss attributable to stockholders was $(7.33) million for Q2 2026.
- Total revenues for Q2 2026 were $398,657, down from $406,688 in Q2 2025.
- Product revenue increased to $398,657 in Q2 2026 from $244,910 in Q2 2025.
- Net loss per share was $(0.85) for Q2 2026, an improvement from $(1.22) in Q2 2025.
- Cash and cash equivalents increased to $2.79 million as of June 30, 2026, from $1.12 million at year-end 2025.
- Total liabilities decreased to $41.84 million as of June 30, 2026, from $42.49 million at year-end 2025.
- Stockholders' deficit improved to $(33.54) million as of June 30, 2026, from $(35.59) million at year-end 2025.
- A one-for-twenty reverse stock split was effected in April 2026.
Price Impact
More from VNRX